Results 31 to 40 of about 1,198,663 (392)

Adjuvant system AS01: helping to overcome the challenges of modern vaccines

Expert Review of Vaccines, 2017
Introduction: Adjuvants are used to improve vaccine immunogenicity and efficacy by enhancing antigen presentation to antigen-specific immune cells with the aim to confer long-term protection against targeted pathogens.
Arnaud M. Didierlaurent, Béatrice Laupèze, Alberta Di Pasquale, Nadia Hergli, Catherine Collignon, Nathalie Garçon   +5 more
doaj   +1 more source

Oral administration of Blautia wexlerae ameliorates obesity and type 2 diabetes via metabolic remodeling of the gut microbiota

Nature Communications, 2022
Here, the authors inversely associate Blautia wexlerae with obesity and type 2 diabetes mellitus in humans and further show that administration of B. wexlerae to mice decrease both high-fat diet–induced obesity and diabetes via modulating gut microbial ...
Koji Hosomi, Mayu Saito, Jonguk Park, Haruka Murakami, Naoko Shibata, Masahiro Ando, Takahiro Nagatake, Kana Konishi, Harumi Ohno, Kumpei Tanisawa, Attayeb Mohsen, Yi-An Chen, Hitoshi Kawashima, Yayoi Natsume-Kitatani, Yoshimasa Oka, Hidenori Shimizu, Mari Furuta, Yoko Tojima, Kento Sawane, Azusa Saika, Saki Kondo, Yasunori Yonejima, Haruko Takeyama, Akira Matsutani, Kenji Mizuguchi, Motohiko Miyachi, Jun Kunisawa   +26 more
doaj   +1 more source

Vaccination with complete adjuvant-added inactivated virus vaccine of Japanese encephalitis to swine, rabbits and chicks for preventing viremia (epidemiological study on Japanese encephalitis 25) [PDF]

, 1969
As a step towards the elimination of Japanese encephalitis virus in natural surroundings, we inoculated pigs, rabbits and chicks with inactivated Japanese encephalitis vaccine supplemented with complete or incomplete Freund's adjuvant twice at one-week ...
Jitsunari, Fumihiko, Kitamura, Naoji, Nagao, Yutaka, Ogata, Masana   +3 more
core   +1 more source

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

New England Journal of Medicine, 2005
BACKGROUND Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and safety after excision of early-stage breast cancer and completion of ...
M. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch, D. Cameron, M. Dowsett, C. Barrios, G. Steger, C. Huang, M. Andersson, M. Inbar, M. Lichinitser, I. Láng, U. Nitz, H. Iwata, C. Thomssen, C. Lohrisch, T. Suter, J. Rüschoff, T. Suto, V. Greatorex, C. Ward, C. Straehle, E. McFadden, M. Dolci, R. Gelber   +31 more
semanticscholar   +1 more source

Adjuvant treatment with tumor-targeting Salmonella typhimurium A1-R reduces recurrence and increases survival after liver metastasis resection in an orthotopic nude mouse model. [PDF]

, 2015
Colon cancer liver metastasis is often the lethal aspect of this disease. Well-isolated metastases are candidates for surgical resection, but recurrence is common. Better adjuvant treatment is therefore needed to reduce or prevent recurrence.
Bouvet, Michael, Chishima, Takashi, Endo, Itaru, Hiroshima, Yukihiko, Hoffman, Robert M, Murakami, Takashi, Tanaka, Kuniya, Zhang, Yong, Zhao, Ming   +8 more
core   +2 more sources

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

New England Journal of Medicine, 2005
BACKGROUND We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer.
E. Romond, E. Perez, J. Bryant, V. Suman, C. Geyer, N. Davidson, E. Tan-chiu, S. Martino, S. Paik, P. Kaufman, S. Swain, T. Pisansky, L. Fehrenbacher, L. Kutteh, V. Vogel, D. Visscher, G. Yothers, R. Jenkins, Ann M. Brown, S. Dakhil, E. Mamounas, W. Lingle, P. Klein, J. Ingle, N. Wolmark   +24 more
semanticscholar   +1 more source

Cyclic GMP-AMP Triggers Asthma in an IL-33-Dependent Manner That Is Blocked by Amlexanox, a TBK1 Inhibitor

Frontiers in Immunology, 2019
Extracellular host-derived DNA, as one of damage associated molecular patterns (DAMPs), is associated with allergic type 2 immune responses. Immune recognition of such DNA generates the second messenger cyclic GMP-AMP (cGAMP) and induces type-2 immune ...
Koji Ozasa, Koji Ozasa, Burcu Temizoz, Burcu Temizoz, Burcu Temizoz, Burcu Temizoz, Takato Kusakabe, Takato Kusakabe, Takato Kusakabe, Shingo Kobari, Shingo Kobari, Masatoshi Momota, Masatoshi Momota, Cevayir Coban, Cevayir Coban, Cevayir Coban, Shuichi Ito, Kouji Kobiyama, Kouji Kobiyama, Kouji Kobiyama, Kouji Kobiyama, Etsushi Kuroda, Etsushi Kuroda, Etsushi Kuroda, Ken J. Ishii, Ken J. Ishii, Ken J. Ishii, Ken J. Ishii, Ken J. Ishii   +28 more
doaj   +1 more source

Adjuvant Activity of Synthetic Lipid A of Alcaligenes, a Gut-Associated Lymphoid Tissue-Resident Commensal Bacterium, to Augment Antigen-Specific IgG and Th17 Responses in Systemic Vaccine

Vaccines, 2020
Alcaligenes spp. are identified as commensal bacteria and have been found to inhabit Peyer’s patches in the gut. We previously reported that Alcaligenes-derived lipopolysaccharides (LPS) exerted adjuvant activity in systemic vaccination, without ...
Yunru Wang, Koji Hosomi, Atsushi Shimoyama, Ken Yoshii, Haruki Yamaura, Takahiro Nagatake, Tomomi Nishino, Hiroshi Kiyono, Koichi Fukase, Jun Kunisawa   +9 more
doaj   +1 more source

Adherence to adjuvant therapy in post-menopausal breast cancer patients: A review [PDF]

, 2011
This is the post-print version of the Article. The official published version can be accessed from the link below - Copyright @ 2012 John Wiley & Sons, IncThis review aimed to address the concept of adherence to adjuvant therapy in post-menopausal women.
Banning, M
core   +1 more source

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

New England Journal of Medicine, 2018
BACKGROUND Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy.
T. Conroy, P. Hammel, M. Hebbar, M. B. Abdelghani, A. Wei, J. Raoul, L. Choné, E. François, P. Artru, J. Biagi, T. Lecomte, E. Assenat, R. Faroux, M. Ychou, J. Volet, A. Sauvanet, G. Breysacher, F. Di Fioré, C. Cripps, P. Kavan, P. Texereau, K. Bouhier‐Leporrier, F. Khemissa-Akouz, J. Legoux, B. Juzyna, S. Gourgou, C. O'Callaghan, Claire Jouffroy-Zeller, P. Rat, D. Malka, F. Castan, J. Bachet   +31 more
semanticscholar   +1 more source